Oncolytic Peptide VP-315 Reduces Tumor Size in Patients With Basal Cell Carcinoma
VP-315, an oncolytic peptide, showed promising results in reducing tumor size in basal cell carcinoma patients, with 86% experiencing tumor reduction and 51% achieving complete histological clearance. No dose-limiting toxicities were reported, and the agent is being explored as a non-surgical treatment option.
Related Clinical Trials
Reference News
Oncolytic Peptide VP-315 Reduces Tumor Size in Patients With Basal Cell Carcinoma
VP-315, an oncolytic peptide, showed promising results in reducing tumor size in basal cell carcinoma patients, with 86% experiencing tumor reduction and 51% achieving complete histological clearance. No dose-limiting toxicities were reported, and the agent is being explored as a non-surgical treatment option.